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Abstract
Background: Bowel cancer is common and is a major cause of death. Meta-analysis of randomised controlled
trials estimates that screening for colorectal cancer using faecal occult blood (FOB) test reduces mortality from
colorectal cancer by 16%. However, FOB testing has a low positive predictive value, with associated unnecessary
cost, risk and anxiety from subsequent investigation, and is unacceptable to a proportion of the target population.
Increased levels of an enzyme called matrix metalloproteinase 9 (MMP-9) have been found to be associated with
colorectal cancer, and this can be measured from a blood sample. Serum MMP-9 is potentially an accurate, low
risk and cost-effective population screening tool. This study aims to evaluate the accuracy of serum MMP-9 as a
test for colorectal cancer in a primary care population.
Methods/Design: People aged 50 to 69 years, who registered in participating general practices in the West
Midlands Region, will be asked to complete a questionnaire that asks about symptoms. Respondents who describe
any colorectal symptoms (except only abdominal bloating and/or anal symptoms) and are prepared to provide a
blood sample for MMP9 estimation and undergo a colonoscopy (current gold standard investigation) will be
recruited at GP based clinics by a research nurse. Those unfit for colonoscopy will be excluded. Colonoscopies
will be undertaken in dedicated research clinics. The accuracy of MMP-9 will be assessed by comparing the MMP-
9 level with the colonoscopy findings, and the combination of factors (e.g. symptoms and MMP-9 level) that best
predict a diagnosis of malignancy (invasive disease or polyps) will be determined.
Discussion: Colorectal cancer is a major cause of morbidity and mortality. Most colorectal cancers arise from
adenomas and there is a period for early detection by screening, but available tests have risks, are unacceptable
to many, have high false positive rates or are expensive.
This study will establish the potential of serum MMP-9 as a screening test for colorectal cancer. If it is confirmed 
as accurate and acceptable, this serum marker has the potential to assist with reducing the morbidity and 
mortality from colorectal cancer.
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Background
Colorectal cancer is a major public heath problem: it is the
third and second most common invasive malignancy in
men and women, respectively, in England [1]. There are
over 28000 incident cases in England and over 14000
deaths in England and Wales each year [1,2].
The five year age-standardised relative survival rate is less
than 50% for men and women with cancer of the colon
[3]. Survival is strongly associated with stage at presenta-
tion. The five-year relative survival rate for people with
localised cancer is 90%, whereas the rate for those with
distant disease is only 9% [4]. Most colorectal cancers
arise from adenomas, and estimates of the progression
rate suggest that there is a long window period for early
detection by screening and removal of the adenoma [5].
Colorectal cancer, therefore, meets key Wilson and Jung-
ner criteria for a condition that may be a suitable target for
screening [6].
Meta-analysis of randomised controlled trials estimates
that screening for colorectal cancer using faecal occult
blood (FOB) test reduces mortality from colorectal cancer
by 16% [7], but a low positive predictive value (12% for
colorectal cancer) [8] means that most positive tests are
false with associated unnecessary cost, risk and anxiety
from subsequent investigation. Although a UK study is
underway to assess whether flexible sigmoidoscopy
screening can reduce the incidence and mortality of color-
ectal cancer, it will be several years before results show if
incidence/mortality are reduced [9]. Early findings are
promising, but only part of the colon is screened, the test
is costly and invasive, and it has low acceptability: less
than 50% of people aged 50–75 years accepted an invita-
tion for screening [10]. Colonoscopy is the most accurate
way to detect pathology, but it requires secondary care
resources, is unacceptable to some, and has an element of
risk. Combined results from several studies suggest that
the incidence of perforation and haemorrhage in a diag-
nostic colonoscopy are 1 in 603 and 1 in 1352, respec-
tively [11]. A study in the USA found a perforation rate of
1 in 510 within seven days of colonoscopy in people aged
65 years or older, although the rate was lower (1 in 747)
where no indication, for example diverticulosis, was iden-
tified [12]. The cost, low acceptability and risk make
colonoscopy unsuitable as a routine screening test.
FOB testing also has relatively low acceptability, with
reported uptake rates in the UK of only 60% [13]. A blood
test is likely to be a more acceptable routine screening test
than FOB, flexible sigmoidoscopy or colonoscopy. Matrix
metalloproteinases (MMPs) are proteolytic enzymes that
are associated with tissue remodelling in normal and
pathological processes [14]. Over-expression of MMPs has
been correlated with progression in many tumour types,
and over-expression of MMP-9 has been found in colorec-
tal adenomas [15] and carcinomas [16,17]. A significant
positive correlation has also been found between MMP-9
and the stage of colorectal tumours [18]. MMP-9 may be
detected by ELISA assay.
Pilot work
We have completed a pilot study of 300 patients (all
"urgent" referrals) attending a specialist colorectal clinic.
In this high prevalence group (27% with pathology), the
accuracy of serum MMP-9 for colorectal neoplasia was
73% (sensitivity 99%, specificity 63%, positive predictive
value 50%, negative predictive value 99%). Serum MMP-
9, therefore, appears to have the potential to be a useful
screening test for colorectal neoplasia. There is a strong
possibility, however, that our pilot was affected by spec-
trum bias. Although the sensitivity and specificity of a test
are unaffected by disease prevalence, the performance of a
diagnostic test can vary according to the spectrum of the
population being tested, that is the severity and clinical
presentation of the disease [19,20]. Evaluation of the
accuracy and acceptability of serum MMP-9 in a primary
care population, the target population for a potential
screening test, is required to inform the utility of serum
MMP-9 screening in the general population.
Feasibility work for this study has also been undertaken.
One hundred and ninety eight questionnaires were dis-
tributed in December 2003. There was a return rate of
74% (n = 146), and 59% (n = 116) returned a completed
questionnaire. Twenty four respondents (21% of 116)
had symptoms other than only abdominal bloating and/
or anal symptoms, and 13 of these people (54% of 24)
agreed to take part in the study. Eleven, of the 13 agreeing
to take part, were invited to a general practice research
clinic, eight returned the availability slip and seven agreed
to attend. Six of these people attended a research clinic
and all were eligible and consented to have a blood sam-
ple and colonoscopy.
Our pilot work suggests that serum MMP-9 is acceptable
and has a high sensitivity and negative predictive value.
Colorectal cancer is a suitable candidate for mass screen-
ing and a bowel cancer screening programme will be
introduced in the UK with national coverage planned by
2010 [21,22]. Currently available screening tests (FOB,
flexible sigmoidoscopy, colonoscopy) are, however, not
particularly acceptable to the general population and are
either risky or have high false positive rates. Flexible sig-
moidoscopy or colonoscopy screening would also be
expensive and place a considerable burden on existing
resources. Serum MMP-9 is potentially an accurate, low
risk and cost-effective population screening tool. It is,
therefore, important that we evaluate its usefulness in a
primary care population.BMC Cancer 2006, 6:258 http://www.biomedcentral.com/1471-2407/6/258
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Aims and objectives
Aim
To evaluate the accuracy of serum MMP-9 as a test for
colorectal cancer in a primary care population.
Objective
Primary objectives are to evaluate:
(1) the accuracy of serum MMP-9 as a test for colorectal
cancer by comparison with colonoscopy.
(2) the acceptability of serum MMP-9 as a screening test
for colorectal cancer in a primary care population.
Secondary objectives are:
(1) to describe the prevalence of lower gastrointestinal
symptoms in a primary care population.
(2) to assess the appropriateness of current referral guide-
lines.
Methods/Design
Study design
Community based survey with embedded diagnostic test
accuracy evaluation. Accuracy of MMP9 will be assessed
by comparison with the gold standard, colonoscopy. A
cohort aged 50–69 years with lower gastrointestinal
symptoms will be identified using a questionnaire. People
who are willing to participate will be given further infor-
mation at a general practice based research clinic and
informed consent will be obtained. Participants will have
a blood sample for serum MMP-9 determination and a
colonoscopy.
Recruitment of practices
Up to 30 general practices will be recruited. Practices will
be eligible to participate if they are in the catchment area
of University Hospital Birmingham NHS Foundation
Trust.
Eligibility criteria
People aged 50–69 years registered with participating gen-
eral practices.
Exclusion criteria
The GP will exclude people who are under investigation or
treatment for colorectal cancer, unfit for colonoscopy,
unable to give informed consent, or who should not be
invited to take part, in the GPs opinion, for any other rea-
son (e.g. recent bereavement, terminal illness or unable to
give informed consent).
Selection of participants
Lists of eligible persons will be generated from practice
registers. These lists will be scrutinised by GPs, who will
remove all patients deemed inappropriate to receive a
questionnaire (according to criteria defined above).
A postal questionnaire will assess symptoms over the past
three months, the acceptability of screening tests for color-
ectal cancer, risk factors for colorectal cancer, and willing-
ness to take part in the study. The symptoms are based on
the Department of Health (DoH) referral guidelines for
suspected colorectal cancer [23,24]. One reminder will be
sent two weeks later. Respondents who describe any
colorectal symptoms (except only abdominal bloating
and/or anal symptoms) and express willingness to take
part in the evaluation will be sent an information leaflet
and an invitation to attend a research clinic at their gen-
eral practice.
GPs will be notified by fax of people who report symp-
toms that meet the criteria for urgent referral under the
two week standard [24]. Such people will continue to be
eligible for the study, although the GP will be made aware
of their symptoms before the person is invited to a general
practice based research clinic. Regular reports of symp-
toms (except abdominal bloating and anal symptoms)
reported by all respondents will be provided to GPs.
Reports of all people meeting the criteria for urgent refer-
ral and who decide not to fully participate in the study will
be regularly provided to their GP.
Informed consent
At the general practice clinic, the study will be fully
described including potential benefits and risks, fitness
for colonoscopy will be checked, and a basic medical his-
tory will be obtained. Informed consent will be sought
and an appointment for colonoscopy will be arranged for
those providing consent.
Clinical evaluations, laboratory tests and follow-up
Colonoscopies will be performed in a dedicated research
endoscopy facility based in the Wellcome Clinical
Research Facility. Participants will be informed of the
colonoscopy result on the day and the result will also be
sent to their GP. Any participant found to have a malig-
nancy will receive usual care. Two 5 ml blood samples will
be collected immediately before the colonoscopy. One
sample will be sent to the haematology laboratory for rou-
tine analysis (Hb, etc.), the other sample is for MMP-9
determination During transport this samples will be
stored at 4°C. Serum will be stored at -80°C and the
MMP-9 level will be determined on duplicate aliquots of
each sample by ELISA assay. Participants will be flagged
on the NHS Central Register to maximise the ascertain-BMC Cancer 2006, 6:258 http://www.biomedcentral.com/1471-2407/6/258
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ment of malignancy in those with no abnormality
detected on colonoscopy.
Procedures for collecting and handling data
All data will be entered into a password-protected Access
database and each participant will be allocated a unique
study number. Access to the password-protected database
will be restricted to core University of Birmingham staff
working on this study, who are trained in policies and
procedures related to confidentiality. The University is
registered under the data protection act and university
policies and procedures related to confidentiality will be
followed.
Demographic details will be provided by the GP for eligi-
ble people aged 50–69 years. Data on symptoms, risk fac-
tors and the acceptability of screening tests for colorectal
cancer will be collected using the recruitment question-
naire. Participants will also complete a bowel preparation
acceptability questionnaire prior to colonoscopy and two
post-test (colonoscopy) acceptability questionnaires
(prior to discharge at 10 days subsequent to colonos-
copy). Blood sample results and colonoscopy findings
will be communicated to the study team using the unique
study number and linked to patient records.
Justification of sample size
All types of colonic polyps have potential for malignant
change but this is more common with increasing size, a
villous growth pattern and more severe dysplasia [25].
Increasing age, adenoma size and a villous component
have been associated with risk for high grade dysplasia
[26].
In the USA, 11% (n = 329) of 3121 people aged 50–75
years without symptoms of lower gastrointestinal disease
who had a complete colonoscopy had advanced colonic
neoplasia (adenoma with a diameter of at least 10 mm, or
villous features, high grade dysplasia, or invasive cancer)
[27]. If large tubular adenomas were excluded, about 6%
(n = 155) of people had lesions. About 32% (n = 105) of
the 329 people only had lesions proximal to the rectum
and sigmoid colon.
In Norway, 13% (n = 25) of 193 people aged 62–73 years
who were offered a colonoscopy or flexible sigmoidos-
copy and had a full colonoscopy had a high risk adenoma
(adenoma greater than or equal to 10 mm and/or villous
components and/or severe dysplasia) [28]. About 39% (n
= 11) of the 28 high risk lesions were not in the rectum or
sigmoid colon. In the UK, high risk lesions (greater than
or equal to three adenomas, a polyp greater than 1 cm,
tubulovillous or villous histology, severe dysplasia, malig-
nancy, or greater than or equal to 20 hyperplastic polyps)
were found in 5% (n = 1905) of 40674 people aged 55–
64 years who were screened using flexible sigmoidoscopy
[9]. This will not include proximal lesions that could be
found on colonoscopy.
Any test that might usefully be employed to screen for
malignant or premalignant colorectal lesions should have
a high sensitivity to minimise the false negative rate.
Based on our pilot data and conservatively assuming a
community prevalence of 6% [9,27,28]. a sample of 700
people would be sufficient to estimate sensitivity within
3% (95% confidence) and specificity within 4% (95%
confidence). If the community prevalence of high risk
lesions is greater than 6%, our estimate of sensitivity will
have greater precision.
Based on our pilot data (3.0% of the age group being suit-
able and consenting) and a practice list of 4500 with 18%
of people aged 50–69 years [29]. 23100 people from 29
practices will be recruited to identify the 700 participants
needed (Figure 1). The practices will be recruited via the
Midlands GP Research Consortium (MidRec). This is a
network of almost 400 research active practices with
proven success in facilitating recruitment to primary care
based trials. To maximise recruitment, the study has been
designed to have minimal impact on general practices.
Recruitment will be over 20 months.
Methods of data analysis
Primary analysis
(1) ROC curve analysis will be undertaken to determine
cut-off levels.
(2) Sensitivity, specificity, and positive and negative pre-
dictive values will be calculated with confidence intervals.
(3) The combination of MMP-9 level, symptoms, risk fac-
tors and socio-demographic status that best predict inva-
sive and non-invasive colorectal neoplasia will be
described.
(4) The acceptability of serum MMP-9 determination,
FOB testing, flexible sigmoidoscopy and colonoscopy will
be assessed by the initial questionnaire. The acceptability
of serum MMP-9 determination and colonoscopy will
also be assessed by a post-test acceptability questionnaire.
Secondary analysis
Logistic regression analyses of appropriate subgroups (for
example age or symptom profile) will be used to identify
where an alternative cut-off may be more appropriate.
Bias and confounding
There will be duplicate determination of the serum MMP-
9 level and dual data entry. Information on potential con-
founders, for example injuries or chronic illnesses thatBMC Cancer 2006, 6:258 http://www.biomedcentral.com/1471-2407/6/258
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Research plan and study design Figure 1
Research plan and study design.
Covering letter & recruitment 
questionnaire 
n=23100
Non-responders
n=9567
59% (116/198) response rate
Eligible 
n=2800
Invited to general 
practice clinic
n=1517
Colonoscopy, serum MMP-9 
determination, post-test 
acceptability questionnaire, 
outcomes data collected
n=700
54% (13/24) with suitable symptoms express 
willingness to take part in the evaluation
86% (6/7) provided consent for MMP-9 estimation 
Responders
n=13533
Ineligible
n=10733
21% (24/116) with suitable symptoms
Seven of 11 (64%) patients invited to a clinic 
Not invited to general 
practice clinic
n=1283
Did not attend GP clinic
n=552
Attend GP clinic
n=965
Refuse consent or default 
from appointment
n=265
Research plan: Numbers 
shown in grey boxes are 
based on the sample size. 
Response rates are based 
on feasibility work (n=198).BMC Cancer 2006, 6:258 http://www.biomedcentral.com/1471-2407/6/258
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may lead to a raised serum MMP-9, will be collected at the
general practice clinic. National and published data will
be used to identify selection bias based on socio-demo-
graphic or symptom status. The analysis will be adjusted
to take account of any confounders or selection bias. The
blood sample for serum MMP-9 determination will be
taken on the same day as the colonoscopy to improve
comparability. All blood samples will be analysed in the
same laboratory to ensure standardisation of measure-
ment and reporting. The technician doing the MMP-9
ELISA assay and the clinician undertaking the colonos-
copy will be blinded to the patient's symptoms as
reported on the questionnaire.
Ethical approval
This study has been approved by South Birmingham
Research Ethics Committee: reference 05/Q2707/133.
Discussion
Colorectal cancer is a major cause of morbidity and mor-
tality. Most colorectal cancers arise from adenomas and
there is a period for early detection by screening, but avail-
able tests have risks, are unacceptable to many, have high
false positive rates, or are expensive.
A pilot study of patients attending a specialist clinic has
indicated that serum MMP-9 is an accurate and acceptable
test for colorectal cancer. The sensitivity and specificity of
a test can, however, vary in populations with different dis-
ease spectrums. This study will evaluate the accuracy of
serum MMP-9 as a test for colorectal cancer in a primary
care population, the target population for screening.
This study will establish the potential of serum MMP-9 as
a screening test for colorectal cancer. If it is confirmed as
accurate and acceptable, this serum marker has the poten-
tial to assist with reducing morbidity and mortality from
colorectal cancer.
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